Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.

Hillmen P, Rawstron AC, Brock K, Muñoz-Vicente S, Yates FJ, Bishop R, Boucher R, MacDonald D, Fegan C, McCaig A, Schuh A, Pettitt A, Gribben JG, Patten PEM, Devereux S, Bloor A, Fox CP, Forconi F, Munir T.

J Clin Oncol. 2019 Jul 11:JCO1900894. doi: 10.1200/JCO.19.00894. [Epub ahead of print]

PMID:
31295041
2.

A reply to Hurley et al. regarding Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study.

Mayor NP, Hayhurst JD, Turner TR, Szydlo RM, Shaw BE, Bultitude WP, Sayno JR, Tavarozzi F, Latham K, Anthias C, Robinson J, Braund H, Danby R, Perry J, Wilson MC, Bloor AJ, McQuaker IG, MacKinnon S, Marks DI, Pagliuca A, Potter MN, Potter VT, Russell NH, Thomson KJ, Madrigal JA, Marsh SGE.

Biol Blood Marrow Transplant. 2019 Jun 11. pii: S1083-8791(19)30369-6. doi: 10.1016/j.bbmt.2019.06.005. [Epub ahead of print] No abstract available.

PMID:
31195138
3.

Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study.

Mayor NP, Hayhurst JD, Turner TR, Szydlo RM, Shaw BE, Bultitude WP, Sayno JR, Tavarozzi F, Latham K, Anthias C, Robinson J, Braund H, Danby R, Perry J, Wilson MC, Bloor AJ, McQuaker IG, MacKinnon S, Marks DI, Pagliuca A, Potter MN, Potter VT, Russell NH, Thomson KJ, Madrigal JA, Marsh SGE.

Biol Blood Marrow Transplant. 2019 Mar;25(3):443-450. doi: 10.1016/j.bbmt.2018.12.768.

4.

Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.

Eyre TA, Kirkwood AA, Gohill S, Follows G, Walewska R, Walter H, Cross M, Forconi F, Shah N, Chasty R, Hart A, Broom A, Marr H, Patten PEM, Dann A, Arumainathan A, Munir T, Shankara P, Bloor A, Johnston R, Orchard K, Schuh AH, Fox CP; the UK CLL Forum.

Br J Haematol. 2019 May;185(4):656-669. doi: 10.1111/bjh.15802. Epub 2019 Feb 15.

PMID:
30768675
5.

Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival.

Galleu A, Milojkovic D, Deplano S, Szydlo R, Loaiza S, Wynn R, Marks DI, Richardson D, Orchard K, Kanfer E, Tholouli E, Saif M, Sivaprakasam P, Lawson S, Bloor A, Pagliuca A, Potter V, Mehra V, Snowden JA, Vora A, Kishore B, Hunter H, Apperley JF, Dazzi F.

Br J Haematol. 2019 Apr;185(1):89-92. doi: 10.1111/bjh.15749. Epub 2019 Jan 13.

6.

Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT.

Schmid C, Labopin M, Schaap N, Veelken H, Schleuning M, Stadler M, Finke J, Hurst E, Baron F, Ringden O, Bug G, Blaise D, Tischer J, Bloor A, Esteve J, Giebel S, Savani B, Gorin NC, Ciceri F, Mohty M, Nagler A; EBMT Acute Leukaemia Working Party.

Br J Haematol. 2019 Mar;184(5):782-787. doi: 10.1111/bjh.15691. Epub 2018 Nov 22.

PMID:
30467839
7.

Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.

Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, Peggs KS, Afanasyev B, Diez-Martin JL, Corradini P, Michonneau D, Robinson S, Gutiérrez García G, Bonifazi F, Yakoub-Agha I, Gülbas Z, Bloor A, Delage J, Esquirol A, Malladi R, Scheid C, El-Cheikh J, Ghesquières H, Montoto S, Dreger P, Sureda A.

Cancer. 2019 Jan 1;125(1):90-98. doi: 10.1002/cncr.31755. Epub 2018 Oct 23.

8.

Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Barrientos JC, O'Brien S, Brown JR, Kay NE, Reddy NM, Coutre S, Tam C, Mulligan S, Jaeger U, Devereux S, Pocock C, Robak T, Schuster SJ, Schuh A, Gill D, Bloor A, Dearden C, Moreno C, Cull G, Hamblin M, Jones JA, Eckert K, Solman IG, Suzuki S, Hsu E, James DF, Byrd JC, Hillmen P.

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):803-813.e7. doi: 10.1016/j.clml.2018.08.007. Epub 2018 Aug 18.

9.

Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline.

Schuh AH, Parry-Jones N, Appleby N, Bloor A, Dearden CE, Fegan C, Follows G, Fox CP, Iyengar S, Kennedy B, McCarthy H, Parry HM, Patten P, Pettitt AR, Ringshausen I, Walewska R, Hillmen P.

Br J Haematol. 2018 Aug;182(3):344-359. doi: 10.1111/bjh.15460. Epub 2018 Jul 15. No abstract available.

PMID:
30009455
10.

Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation.

Czyz A, Labopin M, Giebel S, Socié G, Apperley J, Volin L, Reményi P, Yakoub-Agha I, Orchard K, Michallet M, Stuhler G, Chaganti S, Murray M, Aljurf M, Bloor A, Passweg J, Finke J, Mohty M, Nagler A.

Am J Hematol. 2018 Jun;93(6):778-785. doi: 10.1002/ajh.25091. Epub 2018 Mar 30.

11.

Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.

Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, Blaise D, Afanasyev B, Diez-Martin JL, Sierra J, Bloor A, Martinez C, Robinson S, Malladi R, El-Cheikh J, Corradini P, Montoto S, Dreger P, Sureda A.

Br J Haematol. 2018 Apr;181(1):86-96. doi: 10.1111/bjh.15152. Epub 2018 Feb 22.

PMID:
29468647
12.

Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.

Eyre TA, Fox CP, Boden A, Bloor A, Dungawalla M, Shankara P, Went R, Schuh AH.

Br J Haematol. 2019 Feb;184(4):667-671. doi: 10.1111/bjh.15151. Epub 2018 Feb 22. No abstract available.

PMID:
29468637
13.

Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies.

Paviglianiti A, Ruggeri A, Volt F, Sanz G, Milpied N, Furst S, Esquirol A, Arcese W, Picardi A, Ferra C, Ifrah N, Bourhis JH, Raj K, von dem Borne PA, Sica S, Menard AL, Bloor A, Kenzey C, Gluckman E, Rocha V.

Br J Haematol. 2017 Dec;179(5):790-801. doi: 10.1111/bjh.14962. Epub 2017 Oct 19.

PMID:
29048109
14.

High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.

Akhtar S, Montoto S, Boumendil A, Finel H, Masszi T, Jindra P, Nemet D, Fuhrmann S, Beguin Y, Castagna L, Ferrara F, Capria S, Malladi R, Moraleda JM, Bloor A, Ghesquières H, Meissner J, Sureda A, Dreger P.

Am J Hematol. 2018 Jan;93(1):40-46. doi: 10.1002/ajh.24927. Epub 2017 Nov 9.

15.

Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.

Martínez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, Castagna L, Afanasyev B, Robinson S, Blaise D, Corradini P, Itälä-Remes M, Bermúdez A, Forcade E, Russo D, Potter M, McQuaker G, Yakoub-Agha I, Scheid C, Bloor A, Montoto S, Dreger P, Sureda A; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

J Clin Oncol. 2017 Oct 20;35(30):3425-3432. doi: 10.1200/JCO.2017.72.6869. Epub 2017 Aug 28.

16.

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.

Collett L, Howard DR, Munir T, McParland L, Oughton JB, Rawstron AC, Hockaday A, Dimbleby C, Phillips D, McMahon K, Hulme C, Allsup D, Bloor A, Hillmen P.

Trials. 2017 Aug 22;18(1):387. doi: 10.1186/s13063-017-2138-6.

17.

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.

Pratt G, Yap C, Oldreive C, Slade D, Bishop R, Griffiths M, Dyer MJS, Fegan C, Oscier D, Pettitt A, Matutes E, Devereux S, Allsup D, Bloor A, Hillmen P, Follows G, Rule S, Moss P, Stankovic T.

Br J Haematol. 2018 Aug;182(3):429-433. doi: 10.1111/bjh.14793. Epub 2017 Jun 23. No abstract available.

PMID:
28643365
18.

Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.

Eyre TA, Osborne WL, Gallop-Evans E, Ardeshna KM, Kassam S, Sadullah S, Sidra G, Culligan D, Arumainathan A, Shankara P, Bowles KM, Eyre DW, Peng YY, Pettengell R, Bloor A, Vandenberghe E, Collins GP.

Br J Haematol. 2018 May;181(4):555-559. doi: 10.1111/bjh.14665. Epub 2017 Mar 24. No abstract available.

PMID:
28342183
19.

Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.

Munir T, Howard DR, McParland L, Pocock C, Rawstron AC, Hockaday A, Varghese A, Hamblin M, Bloor A, Pettitt A, Fegan C, Blundell J, Gribben JG, Phillips D, Hillmen P.

Leukemia. 2017 Oct;31(10):2085-2093. doi: 10.1038/leu.2017.65. Epub 2017 Apr 20.

20.

Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT.

Pavlů J, Labopin M, Zoellner AK, Sakellari I, Stelljes M, Finke J, Fanin R, Stuhler G, Afanasyev BV, Bloor AJ, Anagnostopoulos A, Mohty M, Giebel S, Nagler A.

Cancer. 2017 Jun 1;123(11):1965-1970. doi: 10.1002/cncr.30604. Epub 2017 Feb 17.

21.

Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT.

Battipaglia G, Labopin M, Candoni A, Fanin R, El Cheikh J, Blaise D, Michallet M, Ruggeri A, Contentin N, Ribera JM, Stadler M, Sierra J, von dem Borne PA, Bloor A, Socié G, Nagler A, Mohty M.

Bone Marrow Transplant. 2017 Apr;52(4):592-599. doi: 10.1038/bmt.2016.302. Epub 2017 Jan 16.

PMID:
28092357
22.

Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation.

Radford J, McKay P, Malladi R, Johnson R, Bloor A, Percival F, Sureda A, Peggs KS.

Bone Marrow Transplant. 2017 Mar;52(3):452-454. doi: 10.1038/bmt.2016.244. Epub 2017 Jan 16. No abstract available.

23.

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.

Howard DR, Munir T, Hockaday A, Rawstron AC, Collett L, Oughton JB, Allsup D, Bloor A, Phillips D, Hillmen P.

Trials. 2016 Sep 20;17(1):456. doi: 10.1186/s13063-016-1581-0.

24.

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome.

Eyre TA, Clifford R, Bloor A, Boyle L, Roberts C, Cabes M, Collins GP, Devereux S, Follows G, Fox CP, Gribben J, Hillmen P, Hatton CS, Littlewood TJ, McCarthy H, Murray J, Pettitt AR, Soilleux E, Stamatopoulos B, Love SB, Wotherspoon A, Schuh A.

Br J Haematol. 2016 Oct;175(1):43-54. doi: 10.1111/bjh.14177. Epub 2016 Jul 5.

PMID:
27378086
25.

Recent advances in therapy of chronic lymphocytic leukaemia.

Routledge DJ, Bloor AJ.

Br J Haematol. 2016 Aug;174(3):351-67. doi: 10.1111/bjh.14184. Epub 2016 Jun 13. Review.

PMID:
27291144
26.

Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.

Reyal Y, Kayani I, Bloor AJC, Fox CP, Chakraverty R, Sjursen AM, Fielding AK, Ben Taylor M, Bishton MJ, Morris EC, Thomson KJ, Russell N, Mackinnon S, Peggs KS.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1234-1241. doi: 10.1016/j.bbmt.2016.03.034. Epub 2016 Apr 14.

27.

Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6-LYN gene fusion.

Telford N, Alexander S, McGinn OJ, Williams M, Wood KM, Bloor A, Saha V.

Blood Cancer J. 2016 Apr 8;6:e412. doi: 10.1038/bcj.2016.11. No abstract available.

28.

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.

Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlikova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E.

Haematologica. 2015 Apr;100(4):511-6. doi: 10.3324/haematol.2014.118158. Epub 2015 Jan 16.

29.

Survival outcomes and treatment costs for patients with double-refractory chronic lymphocytic leukaemia (DR-CLL).

Bloor A, De Cock E, Hatswell AJ, Wasiak R, Elvidge J, Stapelkamp C, Hadjivassileva T, Haiderali A, Delgado J.

Br J Haematol. 2015 May;169(3):449-52. doi: 10.1111/bjh.13224. Epub 2014 Nov 20. No abstract available.

PMID:
25410960
30.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators.

N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.

31.

Prognostic factors for mortality with fungal blood stream infections in patients with hematological and non-hematological malignancies.

Salih Z, Cavet J, Dennis M, Somervaille T, Bloor A, Kulkarni S.

South Asian J Cancer. 2013 Oct;2(4):220-4. doi: 10.4103/2278-330X.119920.

32.

Proteomic analysis of Bacillus subtilis strains engineered for improved production of heterologous proteins.

Pohl S, Bhavsar G, Hulme J, Bloor AE, Misirli G, Leckenby MW, Radford DS, Smith W, Wipat A, Williamson ED, Harwood CR, Cranenburgh RM.

Proteomics. 2013 Nov;13(22):3298-308. doi: 10.1002/pmic.201300183. Epub 2013 Oct 27.

PMID:
24115457
33.

Fatal invasive aspergillosis of the larynx.

Williams MS, Ali N, Nonaka D, Bloor AJ, Somervaille TC.

Eur J Haematol. 2013 Apr;90(4):354. doi: 10.1111/ejh.12054. Epub 2013 Jan 4. No abstract available.

PMID:
23227831
34.

Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center.

Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, Radford J.

Haematologica. 2013 Apr;98(4):611-4. doi: 10.3324/haematol.2012.069393. Epub 2012 Oct 12.

35.

Increased severity of acute graft versus host disease as a result of differential expression following a homozygous gene deletion.

Jervis S, Collins P, Tate D, Foster L, Bowman V, Adhern C, Bloor A, Yin J, Wynn R, Poulton K.

Int J Immunogenet. 2013 Apr;40(2):116-9. doi: 10.1111/j.1744-313X.2012.01138.x. Epub 2012 Jun 22.

PMID:
22726315
36.

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, Johnson GG, Schuh A, Matutes E, Dearden CE, Catovsky D, Radford JA, Bloor A, Follows GA, Devereux S, Kruger A, Blundell J, Agrawal S, Allsup D, Proctor S, Heartin E, Oscier D, Hamblin TJ, Rawstron A, Hillmen P.

J Clin Oncol. 2012 May 10;30(14):1647-55. doi: 10.1200/JCO.2011.35.9695. Epub 2012 Apr 9.

PMID:
22493413
37.

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.

Wendtner CM, Hillmen P, Mahadevan D, Bühler A, Uharek L, Coutré S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA.

Leuk Lymphoma. 2012 Mar;53(3):417-23. doi: 10.3109/10428194.2011.618232. Epub 2011 Nov 15.

PMID:
21879809
38.

Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.

Walz C, Erben P, Ritter M, Bloor A, Metzgeroth G, Telford N, Haferlach C, Haferlach T, Gesk S, Score J, Hofmann WK, Hochhaus A, Cross NC, Reiter A.

Blood. 2011 Aug 25;118(8):2239-42. doi: 10.1182/blood-2011-03-343426. Epub 2011 Jun 24.

39.

Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme.

Chowdhury O, Varghese A, Pattinson J, Carrington P, Bloor A, Follows GA, Hillmen P, Schuh A.

Br J Haematol. 2011 Nov;155(4):519-21. doi: 10.1111/j.1365-2141.2011.08711.x. Epub 2011 May 12. No abstract available.

PMID:
21564074
40.

The clinical features and outcome of 2009 H1N1 influenza infection in allo-SCT patients: a British Society of Blood and Marrow Transplantation study.

Protheroe RE, Kirkland KE, Pearce RM, Kaminaris K, Bloor A, Potter MN, Nagra S, Gilleece MH, McQuaker IG, Jackson G, Cook G, Marks DI.

Bone Marrow Transplant. 2012 Jan;47(1):88-94. doi: 10.1038/bmt.2011.12. Epub 2011 Feb 28.

PMID:
21358686
41.

T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.

Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G, Bloor AJ, Clark F, Kazmi M, Linch DC, Chakraverty R, Peggs KS, Mackinnon S.

J Clin Oncol. 2010 Aug 10;28(23):3695-700. doi: 10.1200/JCO.2009.26.9100. Epub 2010 Jul 6.

PMID:
20606089
42.

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.

Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, Milligan D, Collin M, Crawley C, Johnson P, Clark A, Parker A, Bloor A, Pettengell R, Snowden J, Pettitt A, Clark R, Hale G, Peggs K, Thomson K, Morris E, Mackinnon S.

Blood. 2010 Oct 21;116(16):3080-8. doi: 10.1182/blood-2010-05-286856. Epub 2010 Jun 29.

43.

The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.

Stewart WA, Pearce R, Kirkland KE, Bloor A, Thomson K, Apperley J, McQuaker G, Marks DI, Craddock C, McCann S, Russell N, Cook G, Kottaridis PD; British Society for Blood and Marrow Transplantation.

Bone Marrow Transplant. 2010 Nov;45(11):1587-93. doi: 10.1038/bmt.2010.14. Epub 2010 Feb 15.

PMID:
20154739
44.

Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.

Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A, Clark F, Yung L, Linch DC, Chakraverty R, Peggs KS, Mackinnon S.

J Clin Oncol. 2009 Jan 20;27(3):426-32. doi: 10.1200/JCO.2008.17.3328. Epub 2008 Dec 8.

PMID:
19064981
45.

High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.

Bloor AJ, Thomson K, Chowdhry N, Verfuerth S, Ings SJ, Chakraverty R, Linch DC, Goldstone AH, Peggs KS, Mackinnon S.

Biol Blood Marrow Transplant. 2008 Jan;14(1):50-8.

46.

Allogeneic stem cell transplantation as treatment for myelofibrosis.

Papageorgiou SG, Castleton A, Bloor A, Kottaridis PD.

Bone Marrow Transplant. 2006 Dec;38(11):721-7. Epub 2006 Oct 2. Review.

PMID:
17013423
47.

Cerebral tuberculosis post stem cell transplant.

Bloor AJ, Mackinnon S.

Eur J Haematol. 2006 Nov;77(5):456. Epub 2006 Jul 19. No abstract available.

PMID:
16856918
48.
49.

Acquired thrombasthenia due to GPIIbIIIa platelet autoantibodies in a 4-yr-old child.

Bloor AJ, Smith GA, Jaswon M, Parker NE, Ouwehand WH, Liesner R.

Eur J Haematol. 2006 Jan;76(1):89-90. No abstract available.

PMID:
16343278
50.

Left handedness and breast cancer: correlation is spurious.

Bloor AJ.

BMJ. 2005 Oct 29;331(7523):1023-4; author reply 1024. No abstract available.

Supplemental Content

Support Center